Stage IVB Prostate Cancer AJCC v8 Clinical Trials in Seattle, Washington

11 studies are recruiting for stage ivb prostate cancer ajcc v8 in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

   This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by bl…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Pacific Gynecology Specialists, Seattle, Washington

   Locations

   581 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03866382 on ClinicalTrials.gov

2. Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

   This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Swedish Medical Center-First Hill, Seattle, Washington

   Locations

   108 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06632977 on ClinicalTrials.gov

3. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

   This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients wi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center-First Hill, Seattle, Washington

   Locations

   129 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07200830 on ClinicalTrials.gov

4. Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

   This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has s…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT07698535 on ClinicalTrials.gov

5. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

   This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center-Ballard Campus, Seattle, Washington

   Locations

   341 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT04423211 on ClinicalTrials.gov

6. Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

   This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   4 in total

   Run by

   University of Washington

   See if you can join NCT04489719 on ClinicalTrials.gov

7. Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

   This phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (castration-resistant) and that has spread from where it firs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT06236139 on ClinicalTrials.gov

8. Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

   This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate cancer that has not …

   Stage

   Phase 2

   Ages

   Any age

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT06145633 on ClinicalTrials.gov

9. Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

   This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed desp…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT06039371 on ClinicalTrials.gov

10. Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

    This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) com…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Locations

    3 in total

    Run by

    University of Washington

    See if you can join NCT06526299 on ClinicalTrials.gov

11. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation the…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    FHCC South Lake Union, Seattle, Washington

    Locations

    338 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT03678025 on ClinicalTrials.gov